Example: Heart Attack

Search clinical trials for: Dasatinib

Total 287 results

NCT01445509

Completed

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Conditions: Solid Tumors
NCT02689440

Recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
NCT04872790

Not yet recruiting

Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Conditions: B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
NCT00254423

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
NCT04147533

Recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug
NCT04530565

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
NCT02465060

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Conditions: Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Ovarian Carcinoma, Pancreatic Carcinoma, Plasma Cell Myeloma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Plasma Cell Myeloma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
NCT02883049

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions: B Acute Lymphoblastic Leukemia, Central Nervous System Leukemia, Ph-Like Acute Lymphoblastic Leukemia, Testicular Leukemia
NCT04580121

Recruiting

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Conditions: Acute Myeloid Leukemia
NCT03041701

Recruiting

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Conditions: Rhabdomyosarcoma, Rhabdomyosarcoma- Alveolar, Rhabdomyosarcoma-Embryonal
NCT03654768

Recruiting

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
NCT00792948

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
NCT02013648

Active, not recruiting

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Conditions: Acute Myeloid Leukemia (AML)
NCT00070499

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
NCT01636908

Completed

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Conditions: Cancer, Advanced Solid Tumors
NCT04845035

Not yet recruiting

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia
NCT04835584

Not yet recruiting

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia
NCT04830735

Not yet recruiting

Dasatinib for the Treatment of Moderate and Severe COVID-19

Conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed
NCT04685590

Not yet recruiting

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment
NCT02143414

Suspended

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
NCT03595917

Recruiting

ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML

Conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
NCT02750514

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Conditions: Advanced Cancer
NCT00549848

Active, not recruiting

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia
NCT00700882

Completed

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Conditions: Melanoma (Skin)
NCT03193281

Recruiting

KISS Study: Kinase Inhibition With Sprycel Start up

Conditions: Chronic Myeloid Leukemia